- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940998
Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED (Fluid-8)
Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED: a Multicenter, Prospective Study
Primary Objective: To describe the changes in macular fluid within 12 months in patients with neovascular agerelated macular degeneration (nAMD) complicated by pigment epithelial detachment (PED) receiving 8mg aflibercept treatandextend (T&E) therapy.Secondary Objectives:(1) To explore the correlation between changes in macular fluid (e.g., fluctuation index [FI], volume change, etc.) and visual acuity improvement;(2) To evaluate the associations of macular fluid changes (e.g., fluctuation index [FI], volume change, etc.) and different types of fluid components with alterations in retinal and choroidal structures (e.g., disruption of the ellipsoid zone, thickness of each retinal layer, choroidal thickness, microstructural parameters on OCT and OCTA, etc.);(3) To assess the safety of 8mg aflibercept injections in nAMD patients with PED (e.g., incidence rates of retinal pigment epithelium (RPE) tear, elevated intraocular pressure, endophthalmitis and thromboembolic events).
- Study Design (1) Type: Prospective, single-arm, open-label, multicenter study. (2) Sample size: The sample size was calculated based on the Fluid Index (FI) with reference to the results of the TOWER study. The TOWER study described the 24-month macular fluid fluctuation after intravitreal anti-VEGF therapy (bevacizumab, ranibizumab and 2 mg aflibercept) for nAMD in the real-world setting. This study hypothesizes that 8 mg aflibercept is non-inferior to the above three agents in controlling fluid fluctuation. Based on the TOWER study, the assumed mean FI at Month 12 is 42.9 with an SD of 9.8; a sample size of 38 yields a two-sided 95% confidence interval with a half-width of 3.22. Assuming a 20% dropout rate, the minimum number of patients required to reach the primary endpoint is 48. (3) Rationale for indication: The study population consists of patients with nAMD, for which aflibercept is a first-line treatment. The intervention is intravitreal injection of 8 mg aflibercept, whose efficacy and safety have been demonstrated in previous Phase III clinical trials. The T&E regimen is a globally recognized optimized treatment strategy that reduces the treatment burden on patients and healthcare facilities while maintaining sustained disease control.
- Study Procedures This study includes a 3-week screening period to assess subject eligibility, followed by a 48-week treatment period. Subjects who provide consent, meet all inclusion criteria and do not meet any exclusion criteria will receive intravitreal injection of 8 mg aflibercept in the study eye. Referencing the ALTAIR study, this study adopts the T&E (treat-and-extend) regimen: one intravitreal injection is administered at Week 0, Week 4 and Week 8 during the loading phase, and the maintenance phase starts at Week 20. During the maintenance phase, all decisions to extend, maintain or shorten the dosing interval are made according to the T&E criteria. The treatment interval should be shortened if any of the following occurs: new fluid (across all tomographic scans), no improvement or worsening of pre-existing fluid, a loss of ≥5 letters in visual acuity compared with the last visit, an increase of ≥100 μm in CRT in the central 1 mm subfield relative to the previous minimum value, or new neovascularization / new submacular hemorrhage. If the criteria for interval shortening are not met, the current interval will be maintained if fluid persists but shows a continuous decreasing trend; the injection interval may be extended as appropriate if there is no active fluid on OCT. In principle, the injection interval is adjusted within the range of 8-24 weeks, with a default adjustment step of 4 weeks each time.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Honghua Yu
- Telefoonnummer: 0754-88393522
- E-mail: yuhonghua@stu.edu.cn
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
1: (1) Age ≥ 50 years old;
2: (2) Patients with newlydiagnosed or preexisting nAMD and OCTconfirmed PED;
3: (3) Patients who are planned to initiate intravitreal injection of aflibercept 8 mg;
4: (4) Patients voluntarily participate in this study, sign a written informed consent form and are willing to cooperate with followup visits;
5: (5) Patients are assessed by the investigator to have good compliance;
6: (6) If both eyes meet the enrollment criteria, the study eye shall be selected according to the following rules: ① When the bestcorrected visual acuity (BCVA) of the two eyes is different, the eye with poorer visual acuity shall be selected; ② When the BCVA of the two eyes is the same, the right eye shall be selected by default.
Exclusion Criteria:
-
1: (1) Insufficient quality of OCT images, which prevents reliable assessment of Central Retinal Thickness (CST) or Ellipsoid Zone (EZ);
2: (2) Complete absence of the central EZ at baseline, making it impossible to evaluate its changes during followup;
3: (3) Coexistence of other macular diseases that may interfere with the evaluation of macular structure (e.g., Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), etc.);
4: (4) Any condition that may affect patient compliance or scheduled followup (e.g., severe mental disorders, cognitive impairment, substance abuse or addiction, etc.);
5: (5) Participation in any other clinical research project, or having taken part in any drug clinical trial within 6 months prior to screening examinations;
6: (6) Presence of any contraindications listed in the prescribing information for Aflibercept 8 mg;
7: (7) Extraocular/periorbital or intraocular infection or inflammation in either eye at the time of the first study drug injection;
8: (8) The fellow eye is receiving other intravitreal treatments other than Aflibercept;
9: (9) The study eye has received intravitreal antiVEGF injections within the past 3 months, intravitreal glucocorticoid therapy within the past 3 months, or a dexamethasone intravitreal implant within the past 6 months;
10: (10) The patient has a history of immunodeficiency diseases (e.g., HIV, etc.), cancer or malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other illnesses that may significantly reduce life expectancy;
11: (11) Pregnant or lactating women, or women of childbearing potential who are unwilling or unable to use effective contraceptive measures;
12: (12) Known hypersensitivity to any ingredients contained in the study drug;
13: (13) Patients deemed unsuitable for participation in this study by the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Aflibercept 8mg
Intravitreal Injection of Aflibercept 8 mg |
Intravitreal Injection of Aflibercept 8 mg |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Fluctuation Index
Tijdsspanne: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)
|
Parameter source: OCTcentral 1mm CST, including foveal retinal thickness and volume.Calculation formula: FI = Sum of absolute changes in CST between all adjacent visits from baseline to M12 ÷ Number of adjacent intervals. |
Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
BCVA
Tijdsspanne: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)
|
After wearing corrective lenses, outcomes from the ETDRS 4-meter standard protocol or clinical results shall be uniformly converted to ETDRS letter scores; the same method, lighting and distance shall be maintained for the same subject throughout follow-up assessments. |
Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MR-44-26-077408
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .